AHL Investment Management Inc. Has $4.42 Million Stock Holdings in AbbVie Inc. $ABBV

AHL Investment Management Inc. cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 10.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,079 shares of the company’s stock after selling 2,324 shares during the quarter. AbbVie makes up 3.0% of AHL Investment Management Inc.’s portfolio, making the stock its 9th largest position. AHL Investment Management Inc.’s holdings in AbbVie were worth $4,417,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Trust Co of the South raised its holdings in AbbVie by 11.5% during the third quarter. Trust Co of the South now owns 6,664 shares of the company’s stock worth $1,543,000 after acquiring an additional 686 shares in the last quarter. Helen Stephens Group LLC increased its position in shares of AbbVie by 60.1% during the 3rd quarter. Helen Stephens Group LLC now owns 2,107 shares of the company’s stock worth $488,000 after purchasing an additional 791 shares during the last quarter. Investors Research Corp increased its position in shares of AbbVie by 9.5% during the 3rd quarter. Investors Research Corp now owns 926 shares of the company’s stock worth $214,000 after purchasing an additional 80 shares during the last quarter. First Hawaiian Bank raised its stake in shares of AbbVie by 5.1% during the 3rd quarter. First Hawaiian Bank now owns 7,943 shares of the company’s stock worth $1,839,000 after purchasing an additional 387 shares in the last quarter. Finally, Global Wealth Strategies & Associates boosted its holdings in shares of AbbVie by 290.9% in the 3rd quarter. Global Wealth Strategies & Associates now owns 985 shares of the company’s stock valued at $228,000 after buying an additional 733 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

AbbVie stock opened at $227.53 on Tuesday. The firm has a market cap of $402.14 billion, a PE ratio of 172.37, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The stock’s fifty day moving average price is $227.20 and its two-hundred day moving average price is $210.24. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company posted $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ABBV. Evercore ISI boosted their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Guggenheim lifted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. BMO Capital Markets upped their target price on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a report on Friday, September 12th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. Finally, Scotiabank started coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $244.55.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.